New Jersey Senate Bill S1856

New Jersey 2022-2023 Regular Session

• Introduced: 2/28/22
• Refer: 2/28/22

Caption

Requires State and county correctional facilities to offer inmates hepatitis B and hepatitis C testing.

Impact

If enacted, this legislation will initiate a structured approach to addressing hepatitis B and C within the correctional system, potentially leading to heightened awareness and treatment options for inmates. By providing testing as part of the intake process, the bill aims to identify and manage these health concerns more effectively. Given the prevalence of these viruses in correctional settings, the bill's implementation could lead to improved public health outcomes for both inmates and the communities to which they return following incarceration.

Summary

Senate Bill 1856 requires state and county correctional facilities to offer hepatitis B and hepatitis C testing to incarcerated individuals. The bill mandates that upon commencement of confinement, inmates in state facilities must be offered blood testing for these viruses. Similarly, county correctional facilities are required to extend the same testing offer to their incarcerated populations. However, it is important to note that inmates cannot be compelled to undergo this testing; participation is voluntary.

Contention

Debates surrounding the bill may pivot on issues of inmate rights, public health, and the responsibilities of correctional facilities. Supporters may argue that offering testing is a critical step in safeguarding the health of inmates and preventing the spread of diseases within and outside of prison walls. Conversely, opponents might raise concerns about the adequacy of follow-up care or the implications of testing procedures on inmate privacy and consent, emphasizing the need for robust regulations to protect these rights.